A Study of HS-10365 in Patients With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer
Status:
Recruiting
Trial end date:
2028-08-31
Target enrollment:
Participant gender:
Summary
HS-10365 is a small molecular, oral potent, selective RET inhibitor. The purpose of this
study is to investigate the efficacy and safety of HS-10365 in Chinese advanced RET
fusion-positive non-small cell lung cancer patients without any systemic therapy.